Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
PhaseBio could see increase to PB2452 addressable market, says William Blair » 12:20
01/27/20
01/27
12:20
01/27/20
12:20
PHAS

PhaseBio

$5.21 /

-0.09 (-1.70%)

, AZN

AstraZeneca

$48.83 /

-0.45 (-0.91%)

William Blair analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cantor specialty pharma analyst to hold an analyst/industry conference call » 09:25
01/27/20
01/27
09:25
01/27/20
09:25
IMMU

Immunomedics

$18.30 /

-0.24 (-1.29%)

, SGEN

Seattle Genetics

$113.63 /

-1.69 (-1.47%)

, MGNX

MacroGenics

$10.80 /

-0.6 (-5.26%)

, PBYI

Puma Biotechnology

$8.10 /

-0.72 (-8.16%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, ARVN

Arvinas

$50.06 /

-0.78 (-1.53%)

Large Cap & Specialty…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Drug Information Association to hold a conference » 08:00
01/27/20
01/27
08:00
01/27/20
08:00
ABBV

AbbVie

$83.53 /

-1.73 (-2.03%)

, ALLO

Allogene Therapeutics

$23.43 /

-1.29 (-5.22%)

, ALXN

Alexion

$105.24 /

-3.3 (-3.04%)

, BMY

Bristol-Myers

$64.18 /

-2.715 (-4.06%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, CRBP

Corbus Pharmaceuticals

$6.73 /

-0.29 (-4.13%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXPO

Exponent

$72.45 /

-0.9 (-1.23%)

, GSK

GlaxoSmithKline

$47.24 /

-0.605 (-1.26%)

, HALO

Halozyme

$19.07 /

-0.58 (-2.95%)

, IQV

Iqvia

$158.14 /

-2.735 (-1.70%)

, LLY

Eli Lilly

$139.09 /

-2.14 (-1.52%)

, PFE

Pfizer

$39.82 /

-0.89 (-2.19%)

Pharmacovigilance &…

Pharmacovigilance & Risk Management Strategies Conference will be held in Washington, D.C. on January 27-29.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AstraZeneca divests rights to established hypertension medicines » 07:07
01/27/20
01/27
07:07
01/27/20
07:07
AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

AstraZeneca announced…

AstraZeneca announced that it has agreed to sell the global commercial rights to Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma. The agreement excludes the rights in the US and India, which were previously divested, and in Japan, which will be retained by AstraZeneca. The medicines, used primarily to treat hypertension, have lost their patent protection globally. Ruud Dobber, Executive Vice President, BioPharmaceuticals, said: "These are important established medicines, and the divestment to Atnahs ensures they will continue to be available to patients. This transaction supports our strategy to realise value from our portfolio of non-core mature brands, enabling further investment in new medicines." AstraZeneca will continue to manufacture and supply Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs during a transition period. Atnahs will make an upfront payment of $350M to AstraZeneca. AstraZeneca may also receive future sales-contingent payments of up to $40M between 2020 and 2022. Income arising from the upfront and future payments will be reported in AstraZeneca's financial statements within Other Operating Income & Expense. In 2018, Inderal, Tenormin, Tenoretic, Zestril and Zestoretic generated annual sales of $132M in the markets covered by this agreement. The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AstraZeneca reports Brilinta met primary endpoint in Phase 3 THALES trial » 07:01
01/27/20
01/27
07:01
01/27/20
07:01
AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

High-level results from…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AstraZeneca reports Phase 2 DESTINY-Gastric01 trial met primary endpoint » 06:57
01/27/20
01/27
06:57
01/27/20
06:57
AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

High-level results from…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AbbVie, Allergan announce agreement to divest brazikumab, Zenpep » 05:16
01/27/20
01/27
05:16
01/27/20
05:16
ABBV

AbbVie

$83.53 /

-1.73 (-2.03%)

, AGN

Allergan

$188.24 /

-2.28 (-1.20%)

, AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

, NSRGY

Nestle

$0.00 /

+ (+0.00%)

AbbVie (ABBV) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Genentech submits sBLA to FDA for Tecentriq/Avastin combo » 05:12
01/27/20
01/27
05:12
01/27/20
05:12
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Genentech, a member of the Roche Group, announced the completion of a supplemental Biologics License Application, or sBLA, submission to the FDA for Tecentriq in combination with Avastin for the treatment of people with unresectable hepatocellular carcinoma, or HCC, who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. In July 2018, the FDA granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin in HCC based on data from an ongoing Phase Ib trial.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cantor specialty pharma analyst to hold an analyst/industry conference call » 04:55
01/27/20
01/27
04:55
01/27/20
04:55
IMMU

Immunomedics

$18.30 /

-0.24 (-1.29%)

, SGEN

Seattle Genetics

$113.63 /

-1.69 (-1.47%)

, MGNX

MacroGenics

$10.80 /

-0.6 (-5.26%)

, PBYI

Puma Biotechnology

$8.10 /

-0.72 (-8.16%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, ARVN

Arvinas

$50.06 /

-0.78 (-1.53%)

Large Cap & Specialty…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Yesterday
Upgrade
Denali Therapeutics upgraded to Buy from Neutral at Goldman Sachs » 19:59
01/26/20
01/26
19:59
01/26/20
19:59
DNLI

Denali Therapeutics

$24.68 /

-0.26 (-1.04%)

, SNY

Sanofi

$48.73 /

-0.88 (-1.77%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter upgraded Denali Therapeutics (DNLI) to Buy from Neutral with a price target of $37, up from $20. The analyst believes the Denali is evolving into a triple platform story with a small molecule portfolio targeting mutated genetic targets/pathways; a leverageable multi-modality blood brain barrier Transport Vehicle platform; and a potential next-generation viral vector gene therapy vertical. With positive updates from Ph1b DNL201 and Ph1 DNL151, Richter has increased confidence in the program and await initial Sanofi (SNY)-partnered Ph1b DNL747 biomarker data in Alzheimer disease and ALS in mid-2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.